Expert Review of Clinical Immunology

Expert Review of Clinical Immunology is a monthly peer-reviewed journal published by Taylor & Francis, established in 2005, covering therapeutic and diagnostic advances in clinical immunology, with a 2025 impact factor of 4.0（Expert Review of Clinical Immunology）是由（Taylor & Francis）出版的月刊，2005 年创刊，涵盖临床免疫学的治疗与诊断进展，2025 年影响因子为 4.0。

Scope

• It publishes review articles and original papers on new therapeutic and diagnostic modalities in clinical immunology该刊刊载临床免疫学新型治疗与诊断方法的综述与原创论文。
• Key areas include therapeutic overviews of immunologic disorders and the performance of newly approved agents重点领域包括免疫性疾病的治疗综述与对新获批药物疗效的评价。
• It also covers new diagnostic approaches, screening and patient stratification and pharmacoeconomic studies该刊还涵盖新的诊断方法、筛查与患者分层以及药物经济学研究。
• Topics span infection and immunity, inflammation, allergy, autoimmune diseases, transplantation and cancer immunology主题涵盖感染与免疫、炎症、变态反应、自身免疫病、移植免疫与肿瘤免疫。
• The journal does not publish case reports, case series or animal studies该刊不发表病例报告、病例系列或动物研究。

History

• The journal was established in 2005该刊 2005 年创刊。
• It appears in twelve issues a year and is part of the Taylor & Francis Expert Review collection该刊每年出版 12 期，隶属（Taylor & Francis）的「专家评论」系列。
• It is indexed in MEDLINE, Science Citation Index Expanded and Scopus该刊被 MEDLINE、SCIE 与 Scopus 收录。
• Its 2025 impact factor is 4.0, with a five-year impact factor of 4.1其 2025 年影响因子为 4.0，五年影响因子为 4.1。

Editors

• The editor-in-chief is Thomas Forsthuber of the University of Texas at San Antonio, USA现任主编为（University of Texas at San Antonio）的 Thomas Forsthuber。
• Timothy Radstake, formerly of AbbVie, serves as senior editor emeritus曾在（AbbVie）任职的 Timothy Radstake 任荣休资深编辑。
• An International Editorial Advisory Panel of experts from the United States, Europe and Asia identifies review themes由来自（United States）、欧洲与亚洲的专家组成的国际编辑顾问委员会负责确定综述选题。
• Manuscripts are double-anonymously peer reviewed, and guest editorials and drug profiles may be proposed to the commissioning editor稿件实行双向匿名评审，客座社论与药物简介可向组稿编辑提议。